Radiopharmaceuticals for Neuroendocrine Tumors

Keyphrases

• Radiopharmaceuticals 100%
• Neuroendocrine Tumor 100%
• Tumor 33%
• Clinical Outcomes 33%
• Phase II Study 33%
• Somatostatin Receptor 33%
• Therapeutic Potential 33%
• Metastatic Disease 33%
• Patient Selection 33%
• Heterogeneous Groups 33%
• Iodine-131 (131I) 33%
• Advanced or Metastatic 33%
• Therapy Response 33%
• Locally Advanced 33%
• Endocrine Tissues 33%
• Treatment Standards 33%
• Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) 33%
• Delivery Outcomes 33%
• Metastatic Pheochromocytoma 33%
• Metastatic Paraganglioma 33%
• Peptide Receptor Radionuclide Therapy 33%
• Unresectable Locally Advanced 33%
• Clinical Approval 33%
• 177Lu-DOTATATE 33%
• Benzyl Guanidine 33%
• NETTER-1 33%
• Lutathera 33%
• Iobenguane 33%

Medicine and Dentistry

• Neuroendocrine Tumor 100%
• Radiopharmaceutical 100%
• Treatment Response 33%
• Metastatic Carcinoma 33%
• Tumor 33%
• Iodine 131 33%
• Patient Selection 33%
• Pheochromocytoma 33%
• Lutetium 177 33%
• Somatostatin Receptor 33%
• Paraganglioma 33%
• Radionuclide Therapy 33%
• (3 Iodobenzyl)guanidine 33%
• Guanidine 33%
• Gastroenteropancreatic Neuroendocrine Tumor 33%
• Peptide Receptor 33%
• Oxodotreotide Lu 177 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Neuroendocrine Tumor 100%
• Receptor 33%
• Radioisotope 33%
• Iodine-131 33%
• Pheochromocytoma 33%
• Paraganglioma 33%
• Somatostatin Receptor 33%
• Lutetium 177 33%
• Gastroenteropancreatic Neuroendocrine Tumor 33%
• Oxodotreotide Lu 177 33%
• Iobenguane 33%
• Guanidine 33%